Orkambi is a combination therapy for treatment of cystic fibrosis. The FDA approval for the therapy was announced on July 2nd, 2015.
In this StratAcuity: The Science of People video, watch this Orkambi testimony before the Open Public Hearing OPH portion of the May 12, 2015, Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting in Washington, D.C. by cystic fibrosis patient Kate Marshall.
In March, the U.K. National Institute for Health and Care Excellence (NICE) issued a draft guidance against recommending Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis (CF) since its cost is too high for the low benefits it brings.
Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?